

PROVINCIAL FUNDING SUMMARY

Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma (pCODR 10074)

pERC Recommendation: Recommends with conditions

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: September 19, 2016

This information is current as of May 1, 2019.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Mar 1, 2017	Metastatic or advanced renal cell carcinoma after failure of first-line tyrosine kinase inhibitor (TKI) therapy (SUNItinib, SORAFenib, or pazopanib). Third-line therapy after failure of first-line (SUNItinib, SORAFenib or pazopanib) and second-line TKI (axitinib). Patients are eligible to receive nivolumab or everolimus, but not sequential use of these agents. Good performance status; Adequate hepatic and renal function; Access to a treatment centre with expertise to manage immune-mediated adverse reactions of nivolumab. BC Cancer Agency Compassionate Access Program (CAP) approval must be obtained.
AB	Funded	Apr 3, 2017	Criteria Updated: Wording updated November 28 2017 after a request for advice to pCODR: Nivolumab (single agent) for the treatment of patients with advanced or metastatic renal cell carcinoma with disease progression after at least one prior antiangiogenic systemic treatment (nivolumab sequenced either before or after cabazontinib) and who have good performance status. Treatment should continue until disease progression or unacceptable toxicity.
SK	Funded	Mar 23, 2017	As monotherapy treatment for patients with advanced or metastatic renal cell carcinoma with disease progression after at least one prior anti-angiogenic systemic treatment and who have good performance status.
MB	Funded	Mar 13, 2017	For the treatment of patients with: - Advanced or metastatic renal cell carcinoma AND - Disease progression despite prior treatment with anti-angiogenic therapy for advanced disease AND - An Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
ON	Funded	Mar 21, 2017	Treatment for patients with advanced or metastatic renal cell carcinoma with disease progression after at least one prior anti-angiogenic systemic treatment and who have good performance status.
NS	Funded	Apr 1, 2017	As a single agent treatment option for patients with advanced or metastatic RCC with disease progression after at least one prior anti-angiogenic systemic treatment. Patients should have a good performance status. Treatment duration should continue until unacceptable toxicity or disease progression.
NB	Funded	May 2, 2017	For the treatment of patients with advanced or metastatic renal cell carcinoma with disease progression after at least one prior anti-angiogenic systemic therapy and who have a good performance status. Treatment should be discontinued upon disease progression or unacceptable toxicity.
NL	Funded	Aug 3, 2017	Patients with advanced or metastatic renal cell carcinoma with disease progression after at least one prior anti-angiogenic systemic treatment and who have good performance status. Treatment should continue until disease progression or unacceptable toxicity.
PEI	Funded	Aug 1, 2018	For the treatment of patients with advanced or metastatic renal cell carcinoma with disease progression after at least one prior antiangiogenic systemic therapy and who have a good performance status.